Frankfurt - Delayed Quote ? EUR IRLAB Therapeutics AB (6IRA.F) Follow Compare 1.1700 +0.0150 (+1.30%) At close: November 6 at 8:24 AM GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations IRLAB Publishes Interim Report for the Period January - September 2024 GOTHENBURG, SWEDEN / ACCESSWIRE / October 30, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the ... ACCESSWIRE ? 7 days ago 6IRA.F +1.30% IRLAB Reports Continued Progress Ahead of the Mesdopetam Phase III Program GOTHENBURG, SWEDEN / ACCESSWIRE / October 29, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today reports several ... ACCESSWIRE ? 8 days ago 6IRA.F +1.30% IRLAB: Invitation to the Interim Report for Q3 2024 Presentation and Webcast GOTHENBURG, SWEDEN / ACCESSWIRE / October 28, 2024 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that the company will hold a presentation in conjunction ... ACCESSWIRE ? 9 days ago 6IRA.F +1.30% IRLAB Presents at Redeye Neurology Theme Event GOTHENBURG, SE / ACCESSWIRE / October 18, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, October 18, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? 19 days ago 6IRA.F +1.30% IRLAB Receives Milestone Payment of USD 2.5 million in Conjunction with First Dosing in a Phase I Study with IRL757 in Healthy Older Adults GOTHENBURG, SWEDEN / ACCESSWIRE / October 8, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that dosing ... ACCESSWIRE ? 29 days ago 6IRA.F +1.30% Positive Data from the First Part of IRLAB's Phase I Study with the Drug Candidate IRL757 GOTHENBURG, SE / ACCESSWIRE / October 3, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, October 3 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A) - a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? last month 6IRA.F +1.30% IRLAB has Enrolled the Last Patient in the Phase IIb Study of Pirepemat GOTHENBURG, SWEDEN / ACCESSWIRE / September 30, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, September 30, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company that discovers and develops new treatments for Parkinson's ... ACCESSWIRE ? last month 6IRA.F +1.30% IRLAB Presents at the International Congress of Parkinson's Disease and Movement Disorders(R)(MDS) 2024 GOTHENBURG, SE / ACCESSWIRE / September 25, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, September 25, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company that discovers and develops new treatments for Parkinson's ... ACCESSWIRE ? last month 6IRA.F +1.30% IRLAB Granted Additional Patent for its Drug Candidate Pirepemat Expanding the Patent Protection in the US GOTHENBURG, SE / ACCESSWIRE / September 18, 2024 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, September 18, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? last month 6IRA.F +1.30% IRLAB Participates in Pareto Securities' 15th Annual Healthcare Conference GOTHENBURG, SE / ACCESSWIRE / September 13, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, September 13, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? last month 6IRA.F +1.30% IRLAB Participates in the Event Investing in Life Science: From Seed to Success GOTHENBURG, SE / ACCESSWIRE / September 06, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, September 6, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? last month 6IRA.F +1.30% IRLAB is Granted Additional Patent for Drug Candidate Mesdopetam that Expands its Patent Protection GOTHENBURG, SWEDEN / ACCESSWIRE / September 4, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, September 4, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? 2 months ago 6IRA.F +1.30% IRLAB Publishes Interim Report for the Period January-June 2024 GOTHENBURG, SWEDEN / ACCESSWIRE / July 10, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 10, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? 3 months ago 6IRA.F +1.30% IRLAB: Invitation to the Interim Report for Q2 2024 Presentation and Webcast GOTHENBURG, SE / ACCESSWIRE / July 08, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 8, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, ... ACCESSWIRE ? 3 months ago 6IRA.F +1.30% IRLAB's Phase IIb Study of Pirepemat Can Proceed as Planned after Positive Opinion from External Safety Committee GOTHENBURG, SWEDEN / ACCESSWIRE / July 2, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, July 2, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? 4 months ago 6IRA.F +1.30% IRLAB Participates in Stora Aktiedagarna GOTHENBURG, SWEDEN / ACCESSWIRE / June 11, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, June 11, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's ... ACCESSWIRE ? 4 months ago 6IRA.F +1.30% IRLAB Presents at Redeye Growth Day 30 May GOTHENBURG, SE / ACCESSWIRE / May 28, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden. May 28, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A) - a company discovering and developing novel treatments for Parkinson's disease ... ACCESSWIRE ? 5 months ago 6IRA.F +1.30% IRLAB Appoints Kristina Torfg?rd as New CEO GOTHENBURG, SE / ACCESSWIRE / May 27, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden. May 27, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A) - a company discovering and developing novel treatments for Parkinson's disease ... ACCESSWIRE ? 5 months ago 6IRA.F +1.30% IRLAB Strengthens its Liquidity by Drawing SEK 25 million on a Previously Secured Loan Facility GOTHENBURG, SE / ACCESSWIRE / May 23, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 23, 2024 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, ... ACCESSWIRE ? 5 months ago 6IRA.F +1.30% Report from the Annual General Meeting 2024 of IRLAB Therapeutics AB GOTHENBURG, SWEDEN / ACCESSWIRE / May 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Today, on Wednesday May 22, 2024, IRLAB Therapeutics AB held its Annual General Meeting. The following main resolutions were made upon at the Annual General ... ACCESSWIRE ? 5 months ago 6IRA.F +1.30% Performance Overview Trailing total returns as of 11/6/2024, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index Return 6IRA.F OMX Stockholm 30 Index YTD +68.59% +6.46% 1-Year +111.96% +20.05% 3-Year -72.89% +9.82%
